Back to Search
Start Over
Effect of using fidaxomicin on recurrent Clostridium difficile infection.
- Source :
-
The Journal of hospital infection [J Hosp Infect] 2019 Jun; Vol. 102 (2), pp. 165-167. Date of Electronic Publication: 2019 Jan 04. - Publication Year :
- 2019
-
Abstract
- Fidaxomicin is a macrocyclic antibiotic licensed for treating Clostridium difficile infection (CDI). In the UK, fidaxomicin is often reserved for severe CDI or recurrences. At Queen Elizabeth Hospital Birmingham, all courses of fidaxomicin during 2017/2018 were reviewed. Thirty-eight patients received fidaxomicin, of which 64% responded to treatment when fidaxomicin was given during the first episode of mild CDI. Conversely, all patients with recurrent CDI failed treatment with fidaxomicin. There were mixed results for the use of fidaxomicin for severe CDI, with only 42% of patients responding. These results suggest that fidaxomicin is best suited as a treatment for mild CDI during a patient's first episode.<br /> (Copyright © 2019 The Healthcare Infection Society. Published by Elsevier Ltd. All rights reserved.)
Details
- Language :
- English
- ISSN :
- 1532-2939
- Volume :
- 102
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- The Journal of hospital infection
- Publication Type :
- Academic Journal
- Accession number :
- 30615960
- Full Text :
- https://doi.org/10.1016/j.jhin.2018.12.018